Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis
- PMID: 25831516
- PMCID: PMC4394260
- DOI: 10.1073/pnas.1504022112
Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis
Abstract
Infections caused by antibiotic-resistant bacteria are a rising public health threat and make the identification of new antibiotics a priority. From a cell-based screen for bactericidal compounds against Mycobacterium tuberculosis under nutrient-deprivation conditions we identified auranofin, an orally bioavailable FDA-approved antirheumatic drug, as having potent bactericidal activities against both replicating and nonreplicating M. tuberculosis. We also found that auranofin is active against other Gram-positive bacteria, including Bacillus subtilis and Enterococcus faecalis, and drug-sensitive and drug-resistant strains of Enterococcus faecium and Staphylococcus aureus. Our biochemical studies showed that auranofin inhibits the bacterial thioredoxin reductase, a protein essential in many Gram-positive bacteria for maintaining the thiol-redox balance and protecting against reactive oxidative species. Auranofin decreases the reducing capacity of target bacteria, thereby sensitizing them to oxidative stress. Finally, auranofin was efficacious in a murine model of methicillin-resistant S. aureus infection. These results suggest that the thioredoxin-mediated redox cascade of Gram-positive pathogens is a valid target for the development of antibacterial drugs, and that the existing clinical agent auranofin may be repurposed to aid in the treatment of several important antibiotic-resistant pathogens.
Keywords: Gram-positive; MRSA; auranofin; tuberculosis.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![Fig. 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4394260/bin/pnas.1504022112fig01.gif)
![Fig. 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4394260/bin/pnas.1504022112fig02.gif)
![Fig. 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4394260/bin/pnas.1504022112fig03.gif)
![Fig. 4.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4394260/bin/pnas.1504022112fig04.gif)
Similar articles
-
The mechanism of action of auranofin analogs in B. cenocepacia revealed by chemogenomic profiling.Microbiol Spectr. 2024 Feb 6;12(2):e0320123. doi: 10.1128/spectrum.03201-23. Epub 2024 Jan 11. Microbiol Spectr. 2024. PMID: 38206016 Free PMC article.
-
Ebselen and analogs as inhibitors of Bacillus anthracis thioredoxin reductase and bactericidal antibacterials targeting Bacillus species, Staphylococcus aureus and Mycobacterium tuberculosis.Biochim Biophys Acta. 2016 Jun;1860(6):1265-71. doi: 10.1016/j.bbagen.2016.03.013. Epub 2016 Mar 10. Biochim Biophys Acta. 2016. PMID: 26971857
-
Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin.Future Med Chem. 2016;8(2):117-32. doi: 10.4155/fmc.15.182. Epub 2016 Jan 25. Future Med Chem. 2016. PMID: 26808006 Free PMC article.
-
The thioredoxin antioxidant system.Free Radic Biol Med. 2014 Jan;66:75-87. doi: 10.1016/j.freeradbiomed.2013.07.036. Epub 2013 Jul 27. Free Radic Biol Med. 2014. PMID: 23899494 Review.
-
In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.Clin Microbiol Infect. 2007 Jun;13 Suppl 2:17-24. doi: 10.1111/j.1469-0691.2007.01722.x. Clin Microbiol Infect. 2007. PMID: 17488372 Review.
Cited by
-
Multimodal nanoimmunotherapy engages neutrophils to eliminate Staphylococcus aureus infections.Nat Nanotechnol. 2024 Apr 17. doi: 10.1038/s41565-024-01648-8. Online ahead of print. Nat Nanotechnol. 2024. PMID: 38632494
-
The mechanism of action of auranofin analogs in B. cenocepacia revealed by chemogenomic profiling.Microbiol Spectr. 2024 Feb 6;12(2):e0320123. doi: 10.1128/spectrum.03201-23. Epub 2024 Jan 11. Microbiol Spectr. 2024. PMID: 38206016 Free PMC article.
-
Inhibition of selenoprotein synthesis is not the mechanism by which auranofin inhibits growth of Clostridioides difficile.Sci Rep. 2023 Sep 7;13(1):14733. doi: 10.1038/s41598-023-36796-9. Sci Rep. 2023. PMID: 37679389 Free PMC article.
-
The Use of Particulate Systems for Tuberculosis Prophylaxis and Treatment: Opportunities and Challenges.Microorganisms. 2023 Aug 2;11(8):1988. doi: 10.3390/microorganisms11081988. Microorganisms. 2023. PMID: 37630548 Free PMC article. Review.
-
Auranofin targets UBA1 and enhances UBA1 activity by facilitating ubiquitin trans-thioesterification to E2 ubiquitin-conjugating enzymes.Nat Commun. 2023 Aug 9;14(1):4798. doi: 10.1038/s41467-023-40537-x. Nat Commun. 2023. PMID: 37558718 Free PMC article.
References
-
- Boucher HW, et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12. - PubMed
-
- Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century—a clinical super-challenge. N Engl J Med. 2009;360(5):439–443. - PubMed
-
- Klevens RM, et al. Active Bacterial Core surveillance (ABCs) MRSA Investigators Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298(15):1763–1771. - PubMed
-
- Abubakar I, et al. Drug-resistant tuberculosis: Time for visionary political leadership. Lancet Infect Dis. 2013;13(6):529–539. - PubMed
-
- Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug discovery for tuberculosis. Nature. 2011;469(7331):483–490. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases